



Figure S1



**Figure S2**










Figure S3

**BRCA1-HA-WT**



79.5%

**BRCA1-HA-D5**





81.5%

**HA**





**Cyclin A**

**Merge+DAPI**

**Figure S4**



**Figure S5**

**a****b****c****d****Figure S6**




Figure S7




Figure S8

a


Western blot analysis showing protein expression levels for HA(BRCA1), BRCA1, RAD51, and ACTIN across various siRNA treatments. The treatments are categorized by siRNA type: Control siRNA, siBRCA1, siRAD51, siEXO1/DNA2L, BRCA1-WT, and BRCA1-D5. The lanes are grouped by siRNA type, with each group containing three lanes corresponding to the +, +, and + symbols above the first lane of each group.

siRNA Type	Lane 1 (+)	Lane 2 (+)	Lane 3 (+)
Control siRNA	+++	+++	+++
siBRCA1	++	++	++
siRAD51	+	+	+
siEXO1/DNA2L	+	+	+
BRCA1-WT		++	++
BRCA1-D5			++

Molecular weight markers (191, 51, 39 kDa) are indicated on the left of the blots. Antibody labels are on the right: HA(BRCA1), BRCA1, RAD51, and ACTIN.

b

STGC



control siRNA	+		+		+					
siBRCA1		+	+	+	+	+	+	+	+	
siRAD51			+	+	+	+				
siEXO1/DNA2L							+	+	+	+
BRCA1-WT		+		+			+			
BRCA1-D5			+		+			+		

## Figure S9